Ruben Garcia - FibroBiologics, Common General Counsel
| FBLG Stock | 2.56 0.09 3.64% |
Executive
Ruben Garcia is General Counsel of FibroBiologics, Common Stock
| Address | 455 East Medical Center Boulevard, Houston, TX, United States, 77598 |
| Phone | 281 651 5150 |
| Web | https://www.fibrobiologics.com |
FibroBiologics, Common Management Efficiency
The company has return on total asset (ROA) of (0.6155) % which means that it has lost $0.6155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.3433) %, meaning that it created substantial loss on money invested by shareholders. FibroBiologics, Common's management efficiency ratios could be used to measure how well FibroBiologics, Common manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.46. The FibroBiologics, Common's current Return On Capital Employed is estimated to increase to -3.2. At this time, FibroBiologics, Common's Total Current Assets are most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Debt To Assets is estimated to increase to 2.41, while Total Assets are projected to decrease to roughly 6.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lee Flowers | HCW Biologics | 78 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| RN BSN | Oncolytics Biotech | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| David MS | Ikena Oncology | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Ryan Witt | RenovoRx | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| PMP PEng | Oncolytics Biotech | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| BBA CM | Oncolytics Biotech | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| Amy Levin | Oncolytics Biotech | N/A | |
Management Performance
| Return On Equity | -4.34 | ||||
| Return On Asset | -0.62 |
FibroBiologics, Common Leadership Team
Elected by the shareholders, the FibroBiologics, Common's board of directors comprises two types of representatives: FibroBiologics, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroBiologics,. The board's role is to monitor FibroBiologics, Common's management team and ensure that shareholders' interests are well served. FibroBiologics, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroBiologics, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ruben JD, General Counsel | ||
| Hamid Khoja, Chief Officer | ||
| CFA CPA, Chief Officer | ||
| Ruben Garcia, General Counsel | ||
| CPA BBA, Interim Director | ||
| Peter OHeeron, Chairperson Founder |
FibroBiologics, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroBiologics, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.34 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | 110.48 M | ||||
| Shares Outstanding | 35.26 M | ||||
| Shares Owned By Insiders | 28.28 % | ||||
| Shares Owned By Institutions | 9.63 % | ||||
| Number Of Shares Shorted | 2.53 M | ||||
| Price To Book | 300.03 X | ||||
| EBITDA | (15.9 M) | ||||
| Net Income | (16.48 M) |
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.